Comorbidities in clinical practice. Algorithms for diagnostics and treatment

comorbidities, multimorbidity, risk factors, geriatric comorbidity, diagnostic algorithms, primary and secondary prevention, polypharmacotherapy, safety of treatment

1. Oganov RG, Denisov IN, Simanenkov VI, еt al. Comorbidities in practice. Clinical guidelines. 2017;16(6):5-56. (In Russ.) doi:10.15829/1728-8800-2017-6-5-56.

2. Oxford Centre for Evidence-Based Medicine. https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/

3. Lazebnik LB, Vertkin AL, Konev YuV, et al. Aging: professional medical approach (National leadership). M.: Eksmo, 2014. 320 р. (In Russ.) ISBN 978-5-6996858-9-9.

4. Lazebnik LB, Konev YuV. Historical features and semantic difficulties of using the terms denoting multiplicity of diseases in one patient. Eksperimental’naia i klinicheskaia gastroenterologiia. 2018;154(6):4-9. (In Russ.)

5. Mahmood S, Levy D, Vasan R, Wang T. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2013;383(9921):999-1008. doi:10.1016/S0140-6736(13)61752-3.

6. Shalnova SA, Kontsevaya AM. Methodical recommendations “Monitoring of risk factors for chronic noncommunicable diseases in health care practice”. M.: 2012. 27 р. (In Russ.) Available by: http://www.gnicpm.ru/UserFiles/Metodicheskie_rekomendacii_Monitoring_2012.pdf.

7. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-81. doi:10.1093/eurheartj/ehw106.

8. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373-83.

9. DuGoff EH, Canudas-Romo V, Buttorff C, et al. Multiple chronic conditions and life expectancy: a life table analysis. Med Care. 2014 Aug;52(8):688-94. doi:10.1097/MLR.0000000000000166.

10. Centers for Medicare & Medicaid Services. Chronic conditions overview. 2014. Available at: http://www.cms.gov/Research-Statistics-Data-and-Systems/StatisticsTrends-and-Reports/Chronic-Conditions/index.html.

11. Clinical supervision of patients with chronic non-communicable diseases and patients at high risk of their development. Ed. Boytsov SA, Chuchalin AG. 2014. 112 p. (In Russ.) Elektronic resourse: http://www.gnicpm.ru. ISBN 978-5-9905774-0-4.

12. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39,33: 3021-104. doi:10.1093/eurheartj/ehy339.

13. National clinical guidelines. Ed. Oganov R G. 3rd edition. M.: Silicea-Polygraph. 2010. 592 p. (In Russ.) ISBN 978-5-9901860-3-3.

14. Chazova IE, Mychka VB, Kislyak OA, et al. Diagnosis and treatment of metabolic syndrome. Russian recommendations (second revision). Cardiovascular Therapy and Prevention. 2009;8(6S2):1-29. (In Russ.)

15. Recommendations for the management of patients with metabolic syndrome. Clinical guidelines Ministry of Health of the Russian Federation. 2013. 42 p. (In Russ.) http://www.gipertonik.ru/clinical_recommendations.

16. European recommendations for the prevention of cardiovascular diseases in clinical practice (2016 revision). Cardiovascular Therapy and Prevention. 2017;16(6):7-68. (In Russ.) doi:10.15829/1728-8800-2017-6-7-68.

17. Diagnosis and treatment of non-alcoholic fatty liver disease. Methodical recommendations. Ed. Ivashkin VT. М.: 2015. 38 p. (In Russ.) https://rsls.ru/files/Guidelines-RSLS-NASH-2016-01-03.pdf.

18. Ivashkin VT, Drapkina OM, Korneeva ON. Clinical options of the metabolic syndrome. M.: MIA, 2011. 208 p. (In Russ.) ISBN 978-5-9986-0055-5.

19. Drapkina OM, Fadeeva M. Atherosclerosis — liver disease? Polyclinic doctor’s guide. 2013;10:4-9. (In Russ.)

20. Martsevich SYu, Kutishenko NP, Drozdova LYu, еt al. Ursodeoxycholic acid-enhanced efficiency and safety of statin therapy in patients with liver, gallbladder, and/or biliary tract diseases: The RACURS study. A RAKURS study group of investigators. Terapevticheskiy arkhiv. 2014;12:48-52. (In Russ.) doi:10.17116/terarkh2014861248-52.

21. Diagnosis and treatment of arterial hypertension. Russian Medical Society for Arterial Hypertension VNOK. Russian recommendations (fourth revision). Systemic hypertension. 2010;3:5-26. (In Russ.) http://www.scardio.ru/content/Guidelines/recommendationag-2010.pdf.

22. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996 Nov 16;348(9038):1329-39. doi:10.1016/S0140-6736(96)09457-3.

23. Bhatt DL, Steg PG, Ohman EM, et al. For the REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006 Jan 11;295(2):180-9. doi:10.1001/jama.295.2.180.

24. Nakatani D, Sakata Y, Suna S, еt al. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. Circ J. 2013;77(2):439-46. doi:10.1253/circj.CJ-11-1059.

25. Eikelboom J, Connolly S, Bosch J, еt al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377:1319-30. doi:10.1056/NEJMoa1709118.

26. Bonaca M, Bhatt D, Cohen M, еt al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med. 2015;372:1791-800. doi:10.1056/NEJMoa1500857.

27. Roffi M, Patrono C, Collet J-Ph, еt al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315. doi:10.1093/eurheartj/ehv320.

28. Montalescot G, Sechtem U, Achenbach S, еt al. 2013 ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013 Oct;34(38):2949-3003. doi:10.1093/eurheartj/eht296.

29. Tuomilehto J, Rastenyte D, Birkenhäger W, еt al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med. 1999;340(9):677-84. doi:10.1056/NEJM199903043400902.

30. Nimmrich V, Eckert A. Calcium channel blockers and dementia. Br J Pharmacol. 2013;169(6):1203-10. doi:10.1111/bph.12240.

31. Forette F, Seux M, Staessen JA, еt al. Prevention of dementia in randomised doubleblind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352(9137):1347-51. PMID:9802273.

32. Clinical recommendations for conducting electrophysiological studies, catheter ablation and the use of anti-arrhythmic devices VNOA. M.: MAKS Press. 2013:16- 554. (In Russ.)

33. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation — a translational appraisal. Physiol Rev. 2011 Jan;91(1):265-325. doi:10.1152/physrev.00031.2009.

34. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the ESC. Developed with the special contribution of the EHRA of the ESC. Endorsed by the ESO. Eur Heart J. 2016 Oct 7;37(38):2893- 962. doi:10.1093/eurheartj/ehw210.

35. Priori SG, Blomström-Lundqvist C, Mazzanti A, еt al. ESC recommendations for the treatment of patients with ventricular arrhythmias and the prevention of sudden cardiac death 2015 Russian Journal of Cardiology. 2016;21(7):5-86. (In Russ.) doi:10.15829/1560-4071-2016-7-5-86.

36. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS Expert Consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. 2012;14(4):528-606. doi:10.1093/europace/eus027.

37. Miller ON, Tarasov AV, Dick IS, et al. Antiarrhythmic therapy in patients with atrial fibrillation in chronic heart failure. Research “SPACE”. Practical Medicine. 2013;3(71):145-52. (In Russ.)

38. Miller ON, Tarasov AV, Dick IS, Belyaeva IE. Relief of atrial fibrillation in the prehospital and inpatient stages from the standpoint of evidence-based medicine. Consilium Medicum [Cardiology]. 2016;18(10):8-18. (In Russ.)

39. Guide to cardiac arrhythmias. Ed. Chazov EI, Galitsyn SP. M.: GEOTAR-Media, 2010. 416 p. (In Russ.) Руководство по нарушениям ритма сердца. Под ред. Е. И. Чазова, С. П. Голицина. М.: ГЭОТАР-Медиа, 2010. 416 с. ISBN 978-5-9704164-3-3.

40. Pogosova N, Saner H, Pedersen SS, et al. Psychosocial aspects in cardiac rehabilitation: from theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. Eur J Prev Cardiol. 2015;22:1290-306. doi:10.1177/2047487314543075.

41. Lichtman JH, Froelicher ES, Blumenthal JA, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation. 2014;129:1350-69. doi:10.1161/CIR.0000000000000019.

42. Vinokur VA, Grinevich VB, Ilyashevich IG, et al. Psychosomatic disorders in the practice of the therapist: a guide for doctors. SPb.: SpecLit, 2008. 335 p. (In Russ.) ISBN: 978-5-2990037-6-5.

43. Garganeeva NP, Petrova MM, Evsyukov AA, et al. The influence of depression on the course of coronary heart disease and quality of life. 2014;92(12):30-7. (In Russ.)

44. Yakhno NN, Zakharov VV, Lokshina AB. Dementia. A guide for doctors. Third edition. M.: MEDpress-inform, 2011. 272 p. (In Russ.) ISBN 978-5-98322-723-1.

45. Tkacheva ON, Cherdak MA, Mkhitaryan EA. Acetylsalicylic acid in the prevention of ischemic stroke: ways to increase efficiency and safety. Russian Medical Journal. 2017;(25):1880-3. (In Russ.)

46. Pase МР, Beiser A, Enserro D, et al. Association of Ideal Cardiovascular Health With Vascular Brain Injury and Incident Dementia. Stroke. 2016;47:1201-6. doi:10.1161/STROKEAHA.115.012608.

47. Petrova MM, Shnayder NA, Eremina OV. Cognitive dysfunction in arterial hypertension patients. Cardiovascular Therapy and Prevention. 2008;7(2):36-9. (In Russ.)

48. Trubnikova OA, Kagan ES, Kupriyanova TV, et al. Neuropsychological status of patients with stable coronary artery disease and factors affecting it. Complex problems of cardiovascular diseases. 2017;1:112-21. (In Russ.)

49. Russian clinical guidelines. Rheumatology. Ed. Nasonov EL. M.: GEOTAR-Media, 2017. 464 p. (In Russ.) Российские клинические рекомендации. Ревматология. Под ред. Насонова Е.Л. М.: ГЭОТАР-Медиа, 2017. 464 с. ISBN 978-5-9704-4261-6.

50. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017 Jan;76(1):17- 28. doi:10.1136/annrheumdis-2016-209775.

51. Wang H, Cheng Y, Shao D, et аl. Metabolic syndrome increases the risk for knee osteoarthritis: A meta-analysis. Evid Based Complement Alternat Med. 2016;2016:7242478. doi:10.1155/2016/724247813.

52. Shin D. Association between metabolic syndrome, radiographic knee osteoarthritis, and intensity of knee pain: Results of a national survey. J Clin Endocrinol Metab. 2014 Sep;99(9):3177-83. doi:10.1210/jc.2014-1043.

53. Lim R, Holt A. Hepatitis B and C prophylaxis in patients receiving chemotherapy. Viral Hepat Pract. 2014 Jul 1;6(1):10-3.

54. Hanly JG, Fisk JD, McCurdy G, et al. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol. 2005;32(8):1459-66.

55. Sundquist K, Li X, Hemminki K, Sundquist J. Subsequent Risk of Hospitalization for Neuropsychiatric Disorders in Patients With Rheumatic Diseases. A Nationwide Study From Sweden. Arch Gen Psychiatry. 2008;65(5):501-7. doi:10.1001/archpsyc.65.5.501.

56. Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Sci. 2013;16(5):821-47. PMID: 24393558.

57. Harirforoosh S, Jamali F. Renal adverse effects of non-steroidal antiinflammatory drugs. Expert Opin Drug Saf. 2009 Nov;8(6):669-81. doi:10.1517/14740330903311023.

58. Karateev AE, Nasonov EL, Ivashkin VT, et al. Rational use of nonsteroidal antiinflammatory drugs. Clinical guidelines. Scientific and practical rheumatology. 2018;56:1-29. (In Russ.) doi:10.14412/1995-4484-2018-1-29.

59. Nasonov EL, Yakhno NN, Karateev AE, et al. General principles of treatment for musculoskeletal pain: interdisciplinary consensus. Scientific and practical rheumatology. 2016;54(3):247-65. (In Russ.) doi:10.14412/1995-4484-2016-247-265.

60. Scheiman J. NSAID-induced Gastrointestinal Injury: A Focused Update for Clinicians. J Clin Gastroenterol. 2016 Jan;50(1):5-10. doi:10.1097/MCG.0000000000000432.

61. Zakharova NV, Bakulin IG, Simanenkov VI, Maslygina AA. Review of the Maastricht V / Florence consensus recommendations on the diagnosis and treatment of Helicobacter pylori infection. Farmateka. Gastroenterology. Hepatology. 2016;S5-16:8-26. (In Russ.)

62. Shadi SY, Christie J. Functional Dyspepsia in Review: Pathophysiology and Challenges in the Diagnosis and Management due to Coexisting Gastroesophageal Reflux Disease and Irritable Bowel Syndrome. Gastroenterol Res Pract. 2013;2013:351086. doi:10.1155/2013/351086.

63. Niv Y, Fass R. The role of mucin in GERD and its complications. Nat Rev Gastroenterol Hepatol. 2011 Nov 8;9(1):55-9. doi:10.1038/nrgastro.2011.211.

64. Vanheel H, Vicario M, Vanuytse T, et al. Impaired duodenal mucosal integrity and lowgrade inflammation in functional dyspepsia. Gut. 2015 Feb;64(2):357-8. doi:10.1136/gutjnl-2014-307325.

65. Lee YJ, Park KS. Irritable bowel syndrome: Emerging paradigm in pathophysiology. World J Gastroenterol. 2014; 20(10):2456-69. doi:10.3748/wjg.v20.i10.2456.

66. Arakawa T, Kobayashi K, Yoshikawa T. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998;43(9):5-13.

67. Ivashkin VT, Mayev IV, Lapina TL, et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;1:55-70. (In Russ.) doi:10.22416/1382-4376-2018-28-1-55-70.

68. Tarnawski A, Chai J, Pai R, Chiou S. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci. 2004;49(2):202-9.

69. Gweon T, Park J, Kim BW, et al. Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of GastroEsophageal Reflux Disease. Gut Liver. 2018 Jan 15;12(1):46-50. doi:10.5009/gnl17078.

70. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37-43. doi:10.1016/S0140-6736(12)60240-2.

71. Guiding principles for the care of older adults with multimorbidity: an approach for clinicians: American geriatrics society expert panel on the care of older adults with multimorbidity. J Am Geriatr Soc. 2012;60(10):E1-E25. doi:10.1111/j.1532-5415.2012.04188.x.

72. Salive ME. Multimorbidity in older adults. Epidemiol Rev. 2013;35:75-83.

73. NICE guideline. Multimorbidity: clinical assessment and management. Published: 21 September 2016. nice.org.uk/guidance/ng56.

74. Fried LP, Tangen CM, Walston J, et al. for the Cardiovascular Health Study Collaborative Research Group. Frailty in Older Adults: Evidence for a Phenotype. Journal of Gerontology: J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56.

75. Tkacheva ON, Runikhina NK, Ostapenko VS, et al. Validation of the questionnaire for screening frailty. Successes of gerontology. 2017;2:236-42. (In Russ.)

76. Tkacheva ON, Runikhina NK, Vorobiova NM, et al. Antithrombotic therapy in elderly and senile age: an expert consensus. Cardiovascular Therapy and Prevention. 2017;16(3):4-33. (In Russ.) doi:10.15829/1728-8800-2017-3-4-33

77. Tkacheva ON, Runikhina NK, Kotovskaya YV, et al. Arterial hypertension management in patients aged older than 80 years and patients with the senile asthenia. Cardiovascular Therapy and Prevention. 2017;16(1):8-21. (In Russ.) doi:10.15829/1728-8800-2017-1-8-21.

78. Ganelina IE, Lipovetsky BM, Churina SK, et al. Atherosclerosis of the coronary arteries and coronary heart disease. Ed. Ganelina IE. SPb.: 2012. 320 р. (In Russ.) ISBN: 5-02-026217-X.

79. Hajjar ER, Gray SL, Slattum PW, et al. Geriatrics. In: DiPiro JT, Talbert RL, Yee GC, et al. Pharmacotherapy: a pathophysiologic approach. 9th ed. McGraw-Hill Education. 2014;107-18.

80. Periáñez-Párraga L, Martínez-López I, Ventayol-Bosch P, et al. Drug dosage recommendations in patients with chronic liver disease. Rev Esp Enferm Dig. 2012 Apr;104(4):165-84.

81. Lucena MI, Andrade RJ, Tognoni G, et al. Drug use for non-hepatic associated conditions in patients with liver cirrhosis. Eur J Clin Pharmacol. 2003;59:71-6. doi:10.1007/s00228-003-0586-2.

82. Kostas T, Paquin A, Rudolph JL. Practical Geriatric Assessment. Aging Health. 2013;9(6):579-91.

83. Sloss A, Kluber P. Prescribing in liver disease. Aust Prescrib. 2009;32:32-5. doi:10.18773/austprescr.2009.018.

84. Hulisz D. Drug Therapy Management Series: Geriatric Disorders. https://lms.rn.com/getpdf.php/2055.pdf (August 20, 2014).

85. Kwan D, Farrell B. Polypharmacy: optimizing medication use in elderly patients. CGS Journal of CME. 2014;4(1):21-7.

86. Naples JG, Handler SM, Maher RL, et al. Geriatric Pharmacotherapy and Polypharmacy. In: Fillit HM, Rockwood K, Young JB. Brocklehurst’s Textbook of Geriatric Medicine and Gerontology. 8th ed. Elsevier. 2017:849-54.

87. Iijima K, Ichikawa T, Okada S. Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test. Dig Dis Sci. 2009 Jul;54(7): 1500-7. doi:10.1007/s10620-008-0507-4.